News

February 19, 2015, New York – Precision for Value (www.precisionforvalue.com), a Precision for Medicine Company, which provides health economics, analytics, and marketing communications services to life sciences clients, today announced the expansion of its Health Economics and Outcomes Research...

FDA Grants Priority Review, Assigns Action Date of August 11, 2015 - SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (NASDAQ:EXEL) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Genentech’s New Drug Application (NDA)...

INDIANAPOLIS, Feb. 19, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the...

The clinical trial report “Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H1, 2015” provides data on the Keratoconjunctivitis sicca (Dry Eye) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Keratoconjunctivitis...

Pharma companies have attacked the decision to remove some drugs from England's Cancer Drugs Fund (CDF), in a move aimed at de-listing drugs which don't offer value for money. The list of drugs that will be...

Amgen and Kite Pharma are to collaborate on the development of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite's engineered autologous cell therapy (eACT) platform and Amgen's cancer targets. Seen as the 'next...

US-based Gilead Sciences has entered into an agreement with German Phenex Pharmaceuticals to acquire its Farnesoid X Receptor (FXR) programme, including small molecule FXR agonists to treat liver diseases comprising nonalcoholic steatohepatitis (NASH). As part of...